Nyheter m m

Cision

Episurf Medical AB B15 min. fördröjning

Förändring1.85% Senast1,10 SEK
Köp Sälj Läs mer
		

Episurf: INTERIM REPORT 1 APRIL- 30 JUNE 2019

08:30 We will continue to explore commercialization opportunities for our imaging technology, and we took a first, and very important, step very recently though our first strategic partnership. The orthopaedic industry is dominated by a small number of large, global players. As we have previously communicated, at the right time the company is open to seeking a partnership for some or all of its products in key markets. Second quarter 2019 compared to 2018, Group Gross order intake amounted to SEK 1.3m (1.1) an increase of 21.0% Order backlog amounted to SEK 0.7m (1.1) 14,0% increase in orders for Episealer knee implants during the quarter with 49 (43) approved orders Group net sales Increased by 35.5% to SEK 1.1m (0.8) Loss before tax amounted to SEK -18.9m (-16.2) Earnings per share (weighted average) amounted to SEK -0.42 (-0.45) Significant events during the second quarter Episurf Medical announced and conducted a rights issue and raised approximately SEK 75.2m prior to transaction costs Episurf Medical announced that the EPIC-Knee study now is available at ClinicalTrials.gov and that the patient recruitment in the US was ready to start Prof. Niek van Dijk joined Episurf Medicals Clinical Advisory Board The Episealer implant was highlighted in three scientific publications Clinical data for Episealer was accepted for presentation at a global scientific congress US, Japanese and European patent approvals for Episurf Medical Professor Mats Brittberg, Göteborgs University, presented the Episealer at the ICRS Focus Meeting One Step Cartilage Repair in Rome, 5-7 June The Companys COO Jeanette Spångberg left the company on June 1 and the Companys Chief Regulatory Officer - Regulatory Affairs, Quality and IP, Katarina Flodström, was appointed as new COO. In conjunction to these changes, Michael Näsström was appointed Acting Quality Manager Episurf Medical announced that the Company will terminate the financing agreement with European Select Growth Opportunities Fund Significant events after the second quarter Canadian patent approval for Episurf Medical Episurf Medical enters into its first strategic partnership regarding its AI-based imaging technology For more information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com Veronica Wallin, CFO, Episurf Medical Tel:+46 (0) 700 37 48 95 Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com) About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medicals Episealer individualised implants and Epiguide surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medicals iFidelity system enables implants to be cost-efficiently tailored to each individuals unique injury for the optimal fit and minimal intervention. Episurf Medicals head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the companys website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 19 July 2019. ----------------------------------------------------------- https://news.cision.com/episurf/r/interim-report-1-april--30-june-2019,c2866184 https://mb.cision.com/Main/14691/2866184/1079696.pdf © Cision

Finansiella instrument kan både öka och minska i värde. Det finns en risk att du inte får tillbaka de pengar du investerar. Innan du investerar i en fond bör du läsa informationsbroschyren som finns hos fondbolaget och faktabladet som du hittar i orderläggningsfönstret samt på fondens produktsida på nordnet.se.